Evidence map›Paper›PMID 35615594›Full record

ArticleFrontiers in aging neuroscience2022

HIV-1 gp120 Impairs Spatial Memory Through Cyclic AMP Response Element-Binding Protein.

Jenny Shrestha, Maryline Santerre, Charles N S Allen, Sterling P Arjona, Carmen Merali, Ruma Mukerjee, Kumaraswamy Naidu Chitrala, Jin Park, Asen Bagashev, Viet Bui and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Jenny ShresthaMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Maryline SanterreMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Charles N S AllenMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Sterling P ArjonaMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Carmen MeraliDepartment of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA, United States.
Ruma MukerjeeMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Kumaraswamy Naidu ChitralaFels Cancer Institute for Personalized Medicine Institute, Philadelphia, PA, United States.
Jin ParkMemory and Brain Research Center, Department of Neuroscience, Baylor College of Medicine, Houston, TX, United States.
Asen BagashevMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Viet BuiMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Eliseo A EugeninDepartment of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States.
Salim MeraliDepartment of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA, United States.
Marcus KaulInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
Jeannie ChinMemory and Brain Research Center, Department of Neuroscience, Baylor College of Medicine, Houston, TX, United States.
Bassel E SawayaMolecular Studies of Neurodegenerative Diseases Lab, Philadelphia, PA, United States.
Institute for Neurodegenerative Disorders · USBaylor College of Medicine · USTemple University · USThe University of Texas Medical Branch at Galveston · USUniversity of California, Riverside · US

Funding

Neuroprotection by IFN-beta in AIDSR01MH087332 · NIMH · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI KAUL, MARCUS · 2010 to 2019
$5.2M
Methamphetamine Effect on HIV PersistenceR01DA052209 · NIDA · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI KAUL, MARCUS · 2020 to 2024
$3.2M
Lipocalin-2 in HIV-Associated Neuronal InjuryR01MH104131 · NIMH · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI KAUL, MARCUS · 2015 to 2019
$2.2M
Cysteinyl Leukotrienes in HIV Brain InjuryR01MH105330 · NIMH · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI KAUL, MARCUS · 2015 to 2019
$2.0M
NIDA NIH HHS R01 DA052209NIMH NIH HHS R01 MH087332NIMH NIH HHS R01 MH104131NIMH NIH HHS R01 MH105330
6 · The paper itself

Abstract

HIV-associated neurocognitive disorders (HAND) remain an unsolved problem that persists despite using antiretroviral therapy. We have obtained data showing that HIV-gp120 protein contributes to neurodegeneration through metabolic reprogramming. This led to decreased ATP levels, lower mitochondrial DNA copy numbers, and loss of mitochondria

Indexed as

CREB proteinHIVmitochondrianeurodegenerationrolipram

Identifiers

PMID35615594
PMCPMC9124804
OpenAlexW4229374564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.